Skalli Saadia, Desruet Marie-Dominique, Bourre Jean-Cyril, Caravel Jean-Pierre, Vuillez Jean-Philippe
Pharmacy Department, Hospitalo-University Center of Grenoble, Grenoble, France.
Nephrol Dial Transplant. 2009 Aug;24(8):2598-600. doi: 10.1093/ndt/gfp148. Epub 2009 Apr 15.
One of the current therapeutic approaches in the treatment of osteoblastic bone metastases uses the affinity of Samarium ((153)Sm) ethylene-diamine-tetramethylene phosphonic acid (EDTMP) for bone areas of bone turnover. As Samarium EDTMP is a beta-emitter, the radiotherapy contributes to osteoblastic bone lesion control over time. To date, the safety and effectiveness of Samarium therapy have not been established in patients with renal impairment. In this first report, we describe our experience of use of Samarium EDTMP in conjunction with biphosphonates in a haemodialysis patient for treatment of painful bone metastasis. Encouraging results were obtained in achieving pain control. The use of this radioisotope could be more widely applied to treat haemodialysis patients.
治疗成骨性骨转移的当前治疗方法之一利用钐（(153)Sm）乙二胺四亚甲基膦酸（EDTMP）对骨转换骨区域的亲和力。由于钐EDTMP是一种β发射体，随着时间的推移，放射治疗有助于控制成骨性骨病变。迄今为止，钐治疗在肾功能损害患者中的安全性和有效性尚未确立。在这份首例报告中，我们描述了在一名血液透析患者中联合使用钐EDTMP和双膦酸盐治疗疼痛性骨转移的经验。在实现疼痛控制方面取得了令人鼓舞的结果。这种放射性同位素的使用可更广泛地应用于治疗血液透析患者。
